Hyperbaric Oxygen Therapy and Visual Outcomes in Retinal Artery Occlusion: A Retrospective 24-Year Cohort Study
This 24-year retrospective cohort study found that hyperbaric oxygen therapy was independently associated with significantly improved visual outcomes in patients with acute non-arteritic retinal artery occlusion, even among those presenting with worse baseline vision.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
When a blood vessel in the eye suddenly blocks, the retina—the light-sensitive tissue at the back of the eye—begins to starve. This event, known as a retinal artery occlusion, is an ophthalmic emergency that strikes as suddenly as a stroke in the brain. Without oxygen, the delicate cells responsible for vision can die within minutes, leaving patients with sudden, often severe vision loss. For decades, doctors have struggled to find a reliable way to reverse this damage. Standard treatments, such as eye massages or medications to lower eye pressure, have offered little consistent help, and newer attempts using clot-busting drugs have largely failed to show clear benefits in large trials. The window to save sight is narrow, and the need for an effective treatment remains urgent.
In this context, a team of researchers at Rambam Health Care Campus in Israel looked back over twenty-four years to see if a different approach might work. They focused on hyperbaric oxygen therapy, a treatment where patients breathe pure oxygen inside a pressurized chamber. The idea is simple yet powerful: by forcing more oxygen into the blood plasma, the therapy might allow oxygen to reach the starving inner layers of the retina through a different route, keeping the tissue alive until blood flow can be restored naturally or through other means. The researchers wanted to know if patients who received this therapy actually saw better than those who did not, especially when the treatment was given quickly after symptoms began.
The study examined the records of 181 patients who had suffered either a central retinal artery occlusion, which blocks the main artery feeding the entire retina, or a branch retinal artery occlusion, which affects only a portion of the eye. The team carefully selected patients who had arrived at the hospital within eight hours of their symptoms starting, ensuring that the group receiving the oxygen therapy was being compared against a group that followed the same institutional rules for eligibility. This strict adherence to a time-based protocol helped the researchers avoid the confusion that often plagues medical studies, where treatment decisions are made inconsistently. They compared the visual outcomes of the 106 patients who received the hyperbaric oxygen therapy against the 75 who received standard care without it.
The results revealed a striking pattern. At the moment they arrived at the hospital, the patients who went on to receive the oxygen therapy actually had much worse vision than those who did not. This was a crucial detail, as it meant the group needing the most help was the one being treated. Despite starting with poorer sight, the patients who received the hyperbaric oxygen therapy showed significantly greater improvement by the time they were last checked. In the group with the main artery blocked, the treated patients improved their vision by an average of 0.77 steps on a standard vision scale, compared to only 0.19 steps for the untreated group. The difference was even more pronounced in the group with the branch artery blocked, where the treated patients improved by 0.76 steps versus just 0.07 steps for those without the therapy.
Even after the researchers adjusted their analysis to account for the fact that the treated group started with worse vision and other health differences, the link between the therapy and better outcomes remained strong. The treatment appeared to help patients recover more of their sight, regardless of whether the blockage was in the main artery or a smaller branch. While the final level of vision did not differ drastically between the two groups in a simple comparison, the journey of recovery was clearly more successful for those who received the oxygen. More than half of the treated patients in both groups managed to regain at least three lines of vision on an eye chart, a significant improvement compared to the much smaller fraction of untreated patients who achieved the same result.
Safety was also a key part of the investigation. The researchers reviewed the records of all 134 patients who underwent the therapy to check for any harmful side effects. They found no instances of serious complications, such as seizures or oxygen toxicity. The few side effects that did occur were minor and temporary, including ear pain, sinus discomfort, or mild anxiety from being inside the chamber. These issues were infrequent and did not stop the treatment from being administered. The findings suggest that when given in a controlled setting by experienced staff, the therapy is well-tolerated.
The study does not claim to have solved the mystery of retinal artery occlusion, nor does it prove that the therapy causes the improvement in a definitive, experimental sense. Because the study looked back at past records rather than randomly assigning patients to treatment, there is always a chance that other unseen factors influenced the results. However, the consistency of the findings across different measures of vision, combined with the biological logic of how oxygen reaches the eye, makes a strong case for further investigation. The researchers conclude that their work supports the need for larger, forward-looking studies to confirm whether this therapy can become a standard part of emergency care for sudden vision loss. For now, the data offers a hopeful signal that when time is of the essence, breathing pure oxygen under pressure may help the eye recover from a devastating blockage.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.